Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
In Vitro Susceptibility Patterns of Clinically Important Trichophyton and Epidermophyton Species Against Nine Antifungal Drugs Publisher Pubmed



Badali H1 ; Mohammadi R2 ; Mashedi O3 ; De Hoog GS4, 5, 6, 7, 8, 9 ; Meis JF10, 11
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Mycology and Parasitology, Invasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
  2. 2. Department of Medical Parasitology and Mycology, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Kenya Medical Research Institute, Nairobi, Kenya
  4. 4. CBS-KNAW Fungal Biodiversity Centre, Utrecht, Netherlands
  5. 5. Institute for Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, Netherlands
  6. 6. Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
  7. 7. Peking University Health Science Center, Research Center for Medical Mycology, Beijing, China
  8. 8. Institute of Basic Biology, University of Parana, Curitiba, Brazil
  9. 9. King Abdulaziz University, Jeddah, Saudi Arabia
  10. 10. Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, Netherlands
  11. 11. Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, Netherlands

Source: Mycoses Published:2015


Abstract

Despite the common, worldwide, occurrence of dermatophytes, little information is available regarding susceptibility profiles against currently available and novel antifungal agents. A collection of sixty-eight clinical Trichophyton species and Epidermophyton floccosum were previously identified and verified to the species level by sequencing the internal transcribed spacer (ITS) regions of rDNA. MICs of amphotericin B, fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole, terbinafine and MECs of caspofungin and anidulafungin were performed based on CLSI M38-A2. The resulting MIC90s of all strains were, in increasing order, as follows: terbinafine (0.063mgl-1); posaconazole (1mgl-1); isavuconazole and anidulafungin (2mgl-1); itraconazole, voriconazole, amphotericin B, and caspofungin (4mgl-1) and fluconazole (>64mgl-1). These results confirm that terbinafine is an excellent agent for treatment of dermatophytosis due to T. rubrum, T. mentagrophytes, T. verrucosum, T. schoenleinii and E. floccosum. In addition, the new azoles POS and ISA are potentially useful antifungals to treat dermatophytosis. However, the clinical effectiveness of these novel antifungals remains to be determined. © 2015 Blackwell Verlag GmbH.
Experts (# of related papers)
Other Related Docs
13. Causative Agents of Onychomycosis: A 7-Year Study, Journal of Clinical Laboratory Analysis (2016)
24. A 10-Year Study of Dermatophytoses in Isfahan, Iran, Journal of Clinical Laboratory Analysis (2016)
39. Frequency of Uncommon Clinical Yeast Species Confirmed by Its-Sequencing, Archives of Clinical Infectious Diseases (2019)
44. Otomycosis in Central Iran: A Clinical and Mycological Study, Iranian Red Crescent Medical Journal (2011)